Unveiling the mystery of Riehl's melanosis: An update from pathogenesis, diagnosis to treatment
Pigment Cell Melanoma Res. 2023 Jul 4. doi: 10.1111/pcmr.13108. Online ahead of print.ABSTRACTRiehl's melanosis is a hyperpigmentation disorder that has a significant psychological and social impact on individuals. In the past 10 years, new categories have been developed, raising questions about how to classify Riehl's melanosis. The mechanism of this disease remains unclear, although the type IV hypersensitivity response caused by allergic sensitization, as well as genetic, ultraviolet radiation, and autoimmune factors, is to blame. Clinical manifestation, dermoscopy, reflectance confocal microscopy, patch/photopatch test...
Source: Pigment Cell and Melanoma Research - July 4, 2023 Category: Cytology Authors: Yuecen Ding Zhongyi Xu Leihong Flora Xiang Chengfeng Zhang Source Type: research
Prognostic biomarkers for survival in mucosal melanoma
We present the real-world outcome data in a cohort of genotyped MM patients and assessed the prognostic relevance of pigmentation- and NRAS/KRAS mutation status. We correlated pathological reports and clinical data with overall survival of patients with MM. Furthermore, we performed clinically integrated molecular genotyping and analyzed real world treatment regimens for covariates associated with clinical outcome. We identified 39 patients with available clinical and molecular data. Patients with amelanotic MM had a significantly shorter overall survival (p = .003). In addition, the presence of a NRAS or KRAS mutation was...
Source: Pigment Cell and Melanoma Research - June 30, 2023 Category: Cytology Authors: Julia C Thierauf Stefan T Kaluziak Elizabeth Codd Stacy N Dybel Soma Jobbagy Rashi Purohit Alex A Farahani Aikaterini Dedeilia Vivek Naranbhai Mai P Hoang Adam S Fisch Lauren Ritterhouse Genevieve M Boland Jochen K Lennerz A John Iafrate Source Type: research
Prognostic biomarkers for survival in mucosal melanoma
We present the real-world outcome data in a cohort of genotyped MM patients and assessed the prognostic relevance of pigmentation- and NRAS/KRAS mutation status. We correlated pathological reports and clinical data with overall survival of patients with MM. Furthermore, we performed clinically integrated molecular genotyping and analyzed real world treatment regimens for covariates associated with clinical outcome. We identified 39 patients with available clinical and molecular data. Patients with amelanotic MM had a significantly shorter overall survival (p = .003). In addition, the presence of a NRAS or KRAS mutation was...
Source: Pigment Cell and Melanoma Research - June 30, 2023 Category: Cytology Authors: Julia C Thierauf Stefan T Kaluziak Elizabeth Codd Stacy N Dybel Soma Jobbagy Rashi Purohit Alex A Farahani Aikaterini Dedeilia Vivek Naranbhai Mai P Hoang Adam S Fisch Lauren Ritterhouse Genevieve M Boland Jochen K Lennerz A John Iafrate Source Type: research
Prognostic biomarkers for survival in mucosal melanoma
We present the real-world outcome data in a cohort of genotyped MM patients and assessed the prognostic relevance of pigmentation- and NRAS/KRAS mutation status. We correlated pathological reports and clinical data with overall survival of patients with MM. Furthermore, we performed clinically integrated molecular genotyping and analyzed real world treatment regimens for covariates associated with clinical outcome. We identified 39 patients with available clinical and molecular data. Patients with amelanotic MM had a significantly shorter overall survival (p = .003). In addition, the presence of a NRAS or KRAS mutation was...
Source: Pigment Cell and Melanoma Research - June 30, 2023 Category: Cytology Authors: Julia C Thierauf Stefan T Kaluziak Elizabeth Codd Stacy N Dybel Soma Jobbagy Rashi Purohit Alex A Farahani Aikaterini Dedeilia Vivek Naranbhai Mai P Hoang Adam S Fisch Lauren Ritterhouse Genevieve M Boland Jochen K Lennerz A John Iafrate Source Type: research
The OSUMMER lines: A series of ultraviolet-accelerated NRAS-mutant mouse melanoma cell lines syngeneic to C57BL/6
Pigment Cell Melanoma Res. 2023 Jun 21. doi: 10.1111/pcmr.13107. Online ahead of print.ABSTRACTAn increasing number of cancer subtypes are treated with front-line immunotherapy. However, approaches to overcome primary and acquired resistance remain limited. Preclinical mouse models are often used to investigate resistance mechanisms, novel drug combinations, and delivery methods; yet most of these models lack the genetic diversity and mutational patterns observed in human tumors. Here we describe a series of 13 C57BL/6J melanoma cell lines to address this gap in the field. The Ohio State University-Moffitt Melanoma Exposed...
Source: Pigment Cell and Melanoma Research - June 21, 2023 Category: Cytology Authors: Brandon M Murphy Daelin M Jensen Tiffany E Arnold Renan Aguilar-Valenzuela Jase Hughes Valentina Posada Kimberly T Nguyen Vi T Chu Kenneth Y Tsai Craig J Burd Christin E Burd Source Type: research
